Biotechnology · Kansas City, Kansas, United States
$4.91
-1.41% (-$0.07)2026-07-10
Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Net Income-$9.3M
EPS$-0.95
Market Cap$58.5M
Price Performance
Historical data including institutional events
Company Profile
S
Shane Schaffer
CEO & Executive Director
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
The companyâs lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD.
Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
